Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial.

Patrizia Pasanisi, Andreina Oliverio, Ivan Baldassari, Eleonora Bruno, Elisabetta Venturelli, Manuela Bellegotti, Giuliana Gargano, Daniele Morelli, Antonio Bognanni, Marta Rigoni, Paola Muti, Franco Berrino

Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. · pubmed

Paper

Abstract

The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome (MeMeMe) trial tested whether 1,700 mg/day metformin (MET) with or without a Mediterranean diet (MedDiet) intervention could reduce the cumulative incidence of major noncommunicable diseases in people with metabolic syndrome.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The study investigates the effects of metformin and a Mediterranean diet on the prevention of age-related diseases in individuals with metabolic syndrome, which is relevant to longevity research as it addresses potential interventions that could mitigate age-related health issues. However, while the findings may contribute to understanding dietary and pharmacological approaches to aging, the impact appears to be solid but limited, as it primarily focuses on disease prevention rather than directly addressing the root causes of aging or lifespan extension.

Author of this paper? Send a correction.